Saanroo today announced the publication of a new human clinical study evaluating Trpti™, its bioavailable oleoylethanolamide (OEA) ingredient powered by LipiSperse® technology. Published in the peer-reviewed journal Frontiers in Endocrinology (Impact Factor: 5.7), the study provides new insight into how Trpti supports nutrient sensing and the body’s natural incretin response, further strengthening the scientific foundation behind the ingredient for metabolic health and healthy weight management.
The fixed-sequence, single-blind, placebo-controlled, three-period crossover study enrolled 37 healthy adults with a body mass index (BMI) of 25.0-34.9 kg/m². Volunteers received a single dose of a placebo, 150 mg Trpti, or 300 mg Trpti following an overnight fast. Blood samples were collected over 8 hours, with standardized meals provided at 15 minutes and 4 hours post-dose. Time-course responses of Glucagon-Like Peptide-1(GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), Dipeptidyl peptidase-4 (DPP-4), insulin, glucose, and glucagon were analyzed.
The study found that:
- A single 300 mg dose of Trpti significantly increased post-meal GLP-1 and GIP responses in overweight adults compared with placebo. The effect was observed rapidly, within 15 minutes of ingestion, and recurred after subsequent meals.
- Significant changes in circulating DPP-4 concentration were also observed at later time points, suggesting a potential association between Trpti supplementation and modulation of serum DPP-4. DPP-4 is an enzyme that degrades incretin hormones such as GLP-1 and GIP. By inhibiting DPP-4, Trpti may prevent the degradation of GLP-1 and GIP, allowing them to act with optimal efficacy.
- Participants receiving Trpti consumed significantly less of a standardized meal than those receiving the placebo.
- Trpti was well tolerated, with all safety biomarkers remaining within normal clinical ranges.
- The authors concluded that a single 300 mg dose of Trpti enhances post-meal GLP-1 and GIP responses and demonstrates rapid engagement of GLP-1, GIP and DPP-4, supporting further investigation of its role in nutritional strategies targeting metabolic health.
“The publication marks an important milestone in Saanroo’s expanding body of clinical research on Trpti. While previous clinical studies demonstrated meaningful benefits for healthy weight management, gut microbiome composition, and gut barrier integrity, this latest research helps explain one of the underlying biological mechanisms behind those outcomes by showing that Trpti supports the body’s natural post-meal incretin response following supplementation,” said Pavitra Viswanath, Director of Clinical Affairs. “Each new clinical study deepens our understanding of how Trpti works and provides our customers with even greater confidence in the science supporting the ingredient.The findings also demonstrate rapid engagement of GLP-1, GIP and DPP-4, providing additional insight into the body’s natural incretin response.”
This publication complements Saanroo’s previously published clinical research on Trpti.
In a 12-week randomized, placebo-controlled clinical trial published earlier this year, Trpti significantly increased the abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii, two beneficial bacterial species associated with gut and metabolic health. The study also demonstrated statistically significant weight reduction in participants with a BMI below 35 compared with placebo, while supporting gut barrier integrity and healthy immune signaling.
Together, these published human studies demonstrate that Trpti supports healthy weight management through multiple complementary pathways, including appetite regulation, gut microbiome health, gut barrier function, and the body’s natural incretin response.
“Consumers and brands are looking for ingredients supported by meaningful science,” said John Quilter, CEO at Saanroo. “Rather than relying on a single clinical outcome, we continue to invest in research to strengthen the scientific foundation behind Trpti. Every new study helps us better understand the ingredient, all while giving our customers greater confidence in the science they’re bringing to market.“
Trpti is a bioavailable oleoylethanolamide (OEA) ingredient powered by LipiSperse® technology. Human clinical research has demonstrated Trpti’s ability to support healthy weight management, appetite regulation, gut microbiome composition, gut barrier integrity, and now, the body’s natural incretin response. Trpti can be incorporated into supplements, functional food and beverages, providing brands with a differentiated, science-backed ingredient for next-generation nutritional formulations. Visit www.Saanroo.com to learn more.
Study Reference: Briskey D, Pellow J, Viswanath P and Rao A (2026) Acute TRPTI™ (oleoylethanolamide) supplementation enhances incretin hormone responses: a fixed-sequence crossover study. Front. Endocrinol. 17:1879799. doi: 10.3389/fendo.2026.1879799
